Patient-reported Outcomes in the Treatment of Schizophrenia

Patient-reported Outcomes With Bifeprunox or Olanzapine in the Treatment of Schizophrenia. A Pharmacoeconomic Study Carried Out in Connection With the S1543003 And S1543004 Clinical Trials

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00230828

Enrollment

Unknown

Registered

2005-10-03

Start date

2005-05-31

Completion date

Unknown

Last updated

2013-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols

Interventions

DRUGbifeprunox

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Participate in S1543003 and S1543004 in the U.S. sites

Exclusion criteria

* Participate in S1543003 and S1543004 other than U.S. sites

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026